These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32972045)

  • 1. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis.
    Yang Y; Wang D; Cui L; Ma HH; Zhang L; Lian HY; Zhang Q; Zhao XX; Zhang LP; Zhao YZ; Li N; Wang TY; Li ZG; Zhang R
    Cancer Res Treat; 2021 Jan; 53(1):261-269. PubMed ID: 32972045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
    Cournoyer E; Ferrell J; Sharp S; Ray A; Jordan M; Dandoy C; Grimley M; Roy S; Lorsbach R; Merrow AC; Nelson A; Bartlett A; Picarsic J; Kumar A
    Haematologica; 2024 Apr; 109(4):1137-1148. PubMed ID: 37731389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
    McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
    Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
    Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
    Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement.
    Yao JF; Wang D; Ma HH; Lian HY; Zhang L; Wang TY; Li ZG; Jiang J; Cui L; Zhang R
    J Pediatr; 2022 May; 244():194-202.e5. PubMed ID: 35065150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
    Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
    Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Whitlock JA; Geoerger B; Dunkel IJ; Roughton M; Choi J; Osterloh L; Russo M; Hargrave D
    Blood Adv; 2023 Aug; 7(15):3806-3815. PubMed ID: 36884302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Dabrafenib for three children with brainstem BRAF
    Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
    J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
    Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of BRAF-Inhibitor Therapy in BRAF
    Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
    Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent dabrafenib for
    Bhatia A; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Lacouture ME; Hajdenberg J; Ganzel C; Diamond EL
    Haematologica; 2018 Apr; 103(4):e177-e180. PubMed ID: 29472347
    [No Abstract]   [Full Text] [Related]  

  • 16. Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.
    Grenier-Chartrand F; Barrit S; Racu ML; Luce S; Spitaels J; Sadeghi-Meibodi N; Lebrun L; Salmon I; Lefranc F; De Witte O
    Acta Neurochir (Wien); 2022 Mar; 164(3):737-742. PubMed ID: 35029761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
    Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
    Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
    Martin-Algarra S; Hinshelwood R; Mesnage S; Cebon J; Ferrucci PF; Aglietta M; Neyns B; Chiarion-Sileni V; Lindsay CR; Del Vecchio M; Linardou H; Merelli B; Tonini G; Atkinson V; Freivogel K; Stein D; Dalland L; Lau M; Legenne P; Queirolo P; Millward M
    Melanoma Res; 2019 Oct; 29(5):527-532. PubMed ID: 31095039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Mastropolo R; Close A; Allen SW; McClain KL; Maurer S; Picarsic J
    Blood Adv; 2019 Jun; 3(12):1848-1853. PubMed ID: 31213430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.